Regeneron Pharmaceuticals in Tarrytown announced yesterday they’re beginning late-stage clinical trials evaluating a double antibody cocktail for the treatment and prevention of COVID-19. The trial will evaluate the drug’s ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient.